Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential regulation of kynurenine pathway metabolism by the galantamine-memantine combination in rheumatologic diseases: A hypothesis-driven review.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Paradoxical Expression of Ionotropic Glutamate Receptors in Leucocytes.

Clinical reviews in allergy & immunology·2026
Same author

The Contribution of Paresis, Age, and the Effect of Short Training on Cognitive-Motor Dual-Task Interference After Stroke: A Pilot Study.

Life (Basel, Switzerland)·2025
Same author

Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.

Clinical drug investigation·2025
Same author

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Brain sciences·2025
Same author

The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Jul 14, 2026

High-Quality Seizure-Like Activity from Acute Brain Slices Using a Complementary Metal-Oxide-Semiconductor High-Density Microelectrode Array System
06:28

High-Quality Seizure-Like Activity from Acute Brain Slices Using a Complementary Metal-Oxide-Semiconductor High-Density Microelectrode Array System

Published on: September 27, 2024

AMPA receptor activation reduces epileptiform activity in the rat neocortex.

Jonas I Addae1, Nakisha Ali, Farid F Youssef

  • 1Department of Preclinical Sciences, Faculty of Medical Sciences, University of the West Indies, St. Augustine Campus, Trinidad and Tobago. jaddae@fms.uwi.tt

Brain Research
|June 5, 2007
PubMed
Summary

Topical alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) application suppressed epileptic activity in rat neocortex. This suggests targeting AMPA receptors offers new strategies for controlling seizures.

More Related Videos

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Related Experiment Videos

Last Updated: Jul 14, 2026

High-Quality Seizure-Like Activity from Acute Brain Slices Using a Complementary Metal-Oxide-Semiconductor High-Density Microelectrode Array System
06:28

High-Quality Seizure-Like Activity from Acute Brain Slices Using a Complementary Metal-Oxide-Semiconductor High-Density Microelectrode Array System

Published on: September 27, 2024

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays
10:24

Recording and Modulation of Epileptiform Activity in Rodent Brain Slices Coupled to Microelectrode Arrays

Published on: May 15, 2018

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Area of Science:

  • Neuroscience
  • Epileptology
  • Pharmacology

Background:

  • N-methyl-d-aspartic acid (NMDA) receptor activation contributes to epileptic activity.
  • Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) can prevent NMDA-induced effects.
  • The role of AMPA receptors in modulating bicuculline-induced epilepsy requires further investigation.

Purpose of the Study:

  • To investigate the effect of topical AMPA application on bicuculline-induced epileptic activity in the rat neocortex.
  • To compare the efficacy of AMPA in suppressing epileptiform activity with established antiepileptic drugs.
  • To explore different strategies targeting AMPA receptors for seizure suppression.

Main Methods:

  • Topical application of AMPA (50 microM) to the rat neocortex.
  • Recording of somatosensory evoked potentials (SEPs) and electrocorticogram (ECoG) to monitor epileptic spikes.
  • Administration of bicuculline to induce epileptiform activity.
  • Comparison with diazepam and clomethiazole.
  • Use of AMPA receptor antagonist (CNQX) and cyclothiazide to block AMPA receptor desensitization.
  • Experiments on hippocampal slices to assess AMPA effects on CA1 cells.

Main Results:

  • Topical AMPA application significantly prevented bicuculline-induced epileptiform activity in the neocortex.
  • AMPA's effect was comparable to diazepam and clomethiazole.
  • The AMPA receptor antagonist CNQX and cyclothiazide also suppressed epileptiform activity.
  • AMPA did not affect bicuculline-induced changes in hippocampal CA1 cell populations.
  • These findings indicate that targeting AMPA receptors can suppress neocortical epileptiform activity.

Conclusions:

  • Targeting AMPA receptors presents multiple therapeutic strategies for suppressing neocortical epileptiform activity.
  • Strategies include blocking AMPA receptors, promoting desensitization on pyramidal neurons, or reducing desensitization on inhibitory interneurons.
  • AMPA receptor modulation offers a promising avenue for developing novel antiepileptic treatments.